The timing of the acquisition of a SMARCB1 mutation can have a major impact on which type of tumor develops, as evidenced by the initial discovery of SMARCB1 mutations in both rhabdoid tumor predisposition syndrome and familial schwannomatosis [10,168,169,170]. This evidence concerns the gene SMARCB1 and neoplasm.